InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
12 hedge funds and large institutions have $337K invested in InVivo Therapeutics Holdings Corp in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
20% less funds holding
Funds holding: 15 → 12 (-3)
34% less capital invested
Capital invested by funds: $513K → $337K (-$176K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$27.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24K |
| 2 |
ICM
IMS Capital Management
Portland,
Oregon
|
-$22K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$12K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $241K | +$27.7K | +59 | +10% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $44K | – | – | – |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $13K | – | – | – |
|
4
BlackRock
New York
| $10K | – | – | – |
|
5
Northern Trust
Chicago,
Illinois
| $8K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $7K | +$8.45K | +18 | New |
|
|
PWM
7
Paulson Wealth Management
Wheaton,
Illinois
| $6K | – | – | – |
|
8
Geode Capital Management
Boston,
Massachusetts
| $5K | – | – | – |
|
9
Morgan Stanley
New York
| $2K | – | – | – |
|
|
NCM
10
Next Capital Management
New York
| $1K | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$24K | -43 | Closed |
|
|
ICM
12
IMS Capital Management
Portland,
Oregon
| – | -$22K | -39 | Closed |
|
|
WS
13
Wedbush Securities
Los Angeles,
California
| – | -$12K | -22 | Closed |
|
|
14
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$3K | -6 | Closed |
|
NVIV Hedge Fund Activity: Q3 2019 in Review
12 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2019, worth a combined $337K — down 34% from $513K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NVIV and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $27.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $24K sold.
- 12 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2019, down from 15 in Q2 2019.
- Funds reported $337K of InVivo Therapeutics Holdings Corp stock for Q3 2019, down 34% quarter-over-quarter.
- 1 fund opened new InVivo Therapeutics Holdings Corp positions in Q3 2019 and 4 closed out, a net change of -3 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q3 2019 was Renaissance Technologies, an estimated $27.7K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q3 2019 was Citadel Advisors, an estimated $24K sold.
Based on aggregated 13F filings for Q3 2019.